Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.63 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.52 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.52 |
| ▸ | IDO1 | P14902 | 2/20 | 0.50 |
| ▸ | AGXT | P21549 | 2/20 | 0.50 |
| ▸ | DRD2 | P14416 | 1/20 | 0.49 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.49 |
| ▸ | DAO | P14920 | 2/20 | 0.46 |
| ▸ | MIF | P14174 | 1/20 | 0.46 |
| ▸ | MAOB | P27338 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL931383 | 1.00 | TAAR1 (0.63) | TAAR1TDP1SLC6A3IDO1AGXT | |
| SCHEMBL79429 | 0.87 | TAAR1 (0.59) | TAAR1SLC6A3IDO1AGXTDRD2 | |
| SCHEMBL3371633 | 0.85 | TAAR1 (0.74) | TAAR1SLC6A3IDO1AGXTDRD2 | |
| SCHEMBL27821895 | 0.85 | TAAR1 (0.57) | TAAR1SLC6A3IDO1AGXTDRD2 | |
| SCHEMBL4469226 | 0.84 | TAAR1 (0.55) | TAAR1SLC6A3IDO1AGXTDRD2 | |
| SCHEMBL31035947 | 0.84 | TAAR1 (0.55) | TAAR1SLC6A3IDO1AGXTDRD2 | |
| SCHEMBL4427688 | 0.83 | TDP1 (0.65) | TAAR1TDP1DRD2MAOBALDH1A1 | |
| SCHEMBL30361126 | 0.81 | — | — | |
| SCHEMBL3830 | 0.81 | — | — | |
| SCHEMBL1538139 | 0.79 | TAAR1 (0.54) | TAAR1SLC6A3IDO1AGXTDRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119816484-A | Novel piperazine derivative or salt thereof and pharmaceutical composition | 富士胶片株式会社 | 2025-04-11 | — | — | CN | disclosed |
| EP-4526298-A1 | PYRAZOLE DERIVATIVES AS STING AGONISTS | F. Hoffmann-La Roche AG (CH) | 2025-03-26 | — | — | EP | disclosed |
| CN-119285479-A | Preparation and application of novel MAO-B inhibitor containing tetrahydronaphthalene-1-amine structure | 重庆医科大学 | 2025-01-10 | — | — | CN | disclosed |
| CN-119212989-A | Pyrazole derivatives as STING agonists | 豪夫迈·罗氏有限公司 | 2024-12-27 | — | — | CN | disclosed |
| US-20240228487-A1 | FUSED HETEROCYCLIC COMPOUND AND APPLICATION THEREOF, PHARMACEUTICAL COMPOSITIONS CONTAINING SAME AND APPLICATION THEREOF | ZHEJIANG UNIVERSITY (CN) | 2024-07-11 | — | — | US | disclosed |
| EP-4306522-A1 | FUSED RING HETEROCYCLIC COMPOUND AND APPLICATION THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME AND APPLICATION THEREOF | Zhejiang University (CN) | 2024-01-17 | — | — | EP | disclosed |
| WO-2023222644-A1 | PYRAZOLE DERIVATIVES AS STING AGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2023-11-23 | — | — | WO | disclosed |
| CN-115867534-A | Non-lysosomal glucosylceramidase inhibitors and uses thereof | 阿勒克图治疗公司 | 2023-03-28 | — | — | CN | disclosed |
| EP-4146624-A1 | NON-LYSOSOMAL GLUCOSYLCERAMIDASE INHIBITORS AND USES THEREOF | Alectos Therapeutics Inc. (CA) | 2023-03-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240228487-A1 | FUSED HETEROCYCLIC COMPOUND AND APPLICATION THEREOF, PHARMACEUTICAL COMPOSITIONS CONTAINING SAME AND APPLICATION THEREOF | TRPM2, TRPM8, TRPM7 | TAAR1 2030/4885TDP1 3066/4885SLC6A3 667/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.